Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

1.010 -0.070 (-6.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 367,474
Open 1.040
Bid (Size) 1.000 (11)
Ask (Size) 1.020 (4)
Prev. Close 1.080
Today's Range 0.9827 - 1.058
52wk Range 0.6138 - 7.452
Shares Outstanding 365,173,471
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-9.0%
-9.0%
1 Month
+11.1%
+11.1%
3 Month
+39.3%
+39.3%
6 Month
-2.9%
-2.9%
1 Year
-83.0%
-83.0%

More News

Read More
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Changes to Board of Directors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert
Via Benzinga
Topics World Trade
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
From Allarity Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
From Allarity Therapeutics, Inc.
Via GlobeNewswire
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
Via Stocktwits
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
From Allarity Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Allarity Therapeutics, Inc. - Common stock publicly traded?
Yes, Allarity Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Allarity Therapeutics, Inc. - Common stock trade on?
Allarity Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allarity Therapeutics, Inc. - Common stock?
The ticker symbol for Allarity Therapeutics, Inc. - Common stock is ALLR on the Nasdaq Stock Market
What is the current price of Allarity Therapeutics, Inc. - Common stock?
The current price of Allarity Therapeutics, Inc. - Common stock is 1.010
When was Allarity Therapeutics, Inc. - Common stock last traded?
The last trade of Allarity Therapeutics, Inc. - Common stock was at 07/11/25 04:00 PM ET
What is the market capitalization of Allarity Therapeutics, Inc. - Common stock?
The market capitalization of Allarity Therapeutics, Inc. - Common stock is 368.83M
How many shares of Allarity Therapeutics, Inc. - Common stock are outstanding?
Allarity Therapeutics, Inc. - Common stock has 369M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.